NCT02557399COMPLETEDanonymous

Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects

Sponsor

Source record

GlaxoSmithKline

Phase

Source record

Phase 4

Modality

AI-normalized

combination therapy

Target

AI-normalized

Clindamycin phosphate (1.2%) and benzoyl peroxide (3%) in a fixed-dose combination gel targeting acne vulgaris lesions.

Indication / condition

AI-normalized

Acne Vulgaris

Intervention

Source record

Duac® fixed dose combination gel, ADA 0.1% gel, CLDM 1% gel

Source & freshness

Source record

NCT ID

NCT02557399

Original source

ClinicalTrials.gov

Source last updated

Aug 20, 2018

Ingested at

Jun 16, 2026

Internal sync

Jun 16, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT02557399

Title

Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects

Sponsor

GlaxoSmithKline

Status

COMPLETED

Phase

Phase 4

Condition raw

Acne Vulgaris

Condition normalized

Acne Vulgaris

Modality raw

combination therapy

Modality normalized

combination therapy

Target raw

Clindamycin phosphate (1.2%) and benzoyl peroxide (3%) in a fixed-dose combination gel targeting acne vulgaris lesions.

Target normalized

Clindamycin phosphate (1.2%) and benzoyl peroxide (3%) in a fixed-dose combination gel targeting acne vulgaris lesions.

Interventions

Duac® fixed dose combination gel, ADA 0.1% gel, CLDM 1% gel

Public preview

Source record

The clinical trial conducted by GlaxoSmithKline (GSK) evaluated the efficacy of Duac® fixed-dose combination gel against a standard combination therapy of adapalene and clindamycin in treating facial acne vulgaris in a Japanese population. With a significant market for acne treatments, particularly in Asia, successful outcomes could enhance GSK's competitive positioning in dermatological therapies. The trial's completion and positive results may facilitate market expansion and reinforce brand loyalty among existing users. Diligence should focus on post-market surveillance and potential regulatory hurdles in other regions.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Clinical Evaluation of Efficacy at 2 Weeks of Duac® Fixed Dose Combination Gel in Treatment of Facial Acne Vulgaris in Japanese Subjects

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 16, 2026

NCT ID

NCT02557399

Status

COMPLETED

Phase

Phase 4

Sponsor

GlaxoSmithKline

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedAug 20, 2018

Internal syncJun 16, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT02557399

Indication

Acne Vulgaris

Modality

combination therapy

Target

Clindamycin phosphate (1.2%) and benzoyl peroxide (3%) in a fixed-dose combination gel targeting acne vulgaris lesions.

Intervention

Duac® fixed dose combination gel, ADA 0.1% gel, CLDM 1% gel

Source record